X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DIFICLIR (fidaxomicin) is a macrolide antibacterial medicine indicated as an initial treatment and first recurrence of Clostridioides difficile infection. Fidaxomicin treats CDI with minimal disruption to the microbiota, helping to preserve colonisation resistance.
Lead Product(s): Fidaxomicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Dificlir
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
Dificlir is an anti-toxin which contains the dynamic substance fidaxomicin used for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients.
Lead Product(s): Fidaxomicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Dificlir
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
Under the agreement, Astellas Europe will transfer its marketing authorizations for Dificlirtm (generic name: fidaxomicin) tablets for Clostridium difficile infections in Europe, Middle East, Africa and selected Commonwealth of Independent States to Tillotts.
Lead Product(s): Fidaxomicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Dificlir
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Astellas Pharma
Deal Size: $130.3 million Upfront Cash: Undisclosed
Deal Type: Agreement November 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
